RAI2: Linking Retinoic Acid Signaling with Metastasis Suppression
Open Access
- 1 May 2015
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (5) , 466-468
Abstract
Summary: Considerable evidence points to the importance of disseminated tumor cells, which are commonly detected in the bone marrow and display features of cellular plasticity, in predicting the clinical outcome of breast cancer. In this issue of Cancer Discovery, Werner and colleagues report on the discovery of retinoic acid–induced 2 (RAI2) as a differentiation factor that suppresses early metastatic spread of estrogen receptor–positive breast cancer. Cancer Discov; 5(5); 466–8. ©2015 AACR. See related article by Werner et al., p. 506Keywords
This publication has 10 references indexed in Scilit:
- Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid–Induced 2Cancer Discovery, 2015
- Targeting tumor–stromal interactions in bone metastasisPharmacology & Therapeutics, 2014
- Tumor Cell Dissemination: Emerging Biological Insights from Animal Models and Cancer PatientsCancer Cell, 2013
- Retinoids, Retinoic Acid Receptors, and CancerAnnual Review of Pathology: Mechanisms of Disease, 2011
- Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast CancerCell, 2009
- The Transcriptional Corepressor CtBP: A Foe of Multiple Tumor SuppressorsCancer Research, 2009
- Towards a proteome-scale map of the human protein–protein interaction networkNature, 2005
- Isolation and Developmental Expression of Retinoic-Acid-Induced GenesDevelopmental Biology, 1994
- Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemiaBlood, 1988
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987